13F reference period
Q2 2026
Security Snapshot
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) Institutional Ownership
CUSIP: 48576U205
13F Institutional Holders and Ownership History from Q1 2025 to Q3 2026
Institutions Reporting
95
Shares (Excl. Options)
21.11M
Full value: 21,114,264 · shares · 30 Jun 2026Price
$9.77
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- KPTI on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 21,114,264
- Total 13F value
- $206,350,504
- Portfolio coverage rank
- 0%
- Share change
- +3,344,795
- Value change
- +$47,473,090
- Number of holders
- 95
- Shares outstanding
- 22,703,733
- SEC-reported price per share
- $0.80
- Insider filing price
- $0.80
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 48576U205.
- 95 institutions reported positions in Q2 2026.
- 13 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 76 to 95 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$97.93M
Full value: $97,927,900 · USD · 31 Mar 2026.$206.35M
Full value: $206,350,504 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 95 institutions filings for Q2 2026.
Security key
48576U205
13F reference period
Q2 2026
13F holders
95
13D/G owners
13
CIK / CUSIP context first
Open Q2 2026 holders
KPTI full holder history
Karyopharm Therapeutics Inc. SEC filings
Karyopharm Therapeutics Inc. company facts
Karyopharm Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 48576U205:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
13
Security
KPTI
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $23,140,165 | 2,302,504 | RA Capital Management, L.P. | 30 Jun 2026 | |||
| Affinity Asset Advisors, LLC | 8.6% | +9.6% | $12,870,974 | +$7,880,460 | 1,713,092 | +158% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| Opaleye Management Inc. | 9.5% | $10,262,842 | 1,569,002 | Opaleye Management Inc. | 10 Oct 2025 | |||
| T. Rowe Price Investment Management, Inc. | 6.6% | -43% | $13,729,191 | -$6,291,044 | 1,539,147 | -31% | T. Rowe Price Investment Management, Inc. | 31 May 2026 |
| Adage Capital Management, L.P. | 6.8% | +220% | $15,444,197 | +$11,055,000 | 1,536,736 | +252% | Adage Capital Management, L.P. | 30 Jun 2026 |
| GOLDMAN SACHS GROUP INC | 6.3% | $14,363,439 | 1,429,198 | THE GOLDMAN SACHS GROUP, INC. | 30 Jun 2026 | |||
| BlackRock, Inc. | 5.6% | $12,369,641 | 1,266,084 | BlackRock, Inc. | 30 Jun 2026 | |||
| ACORN BIOVENTURES, L.P. | 4.5% | -20% | $1,644,885 | -$422,710 | 1,021,668 | -20% | Anders Hove | 02 Oct 2026 |
| J. WOOD CAPITAL ADVISORS LLC | 5% | $6,546,231 | 1,000,708 | J. Wood Capital Advisors LLC | 14 Oct 2025 | |||
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 4.9% | $4,250,895 | 649,984 | HIGHBRIDGE CAPITAL MANAGEMENT, LLC | 30 Sep 2025 | |||
| JPMORGAN CHASE & CO | 4.9% | -6% | $2,797,089 | -$149,213 | 427,624 | -5.1% | JPMORGAN CHASE & CO. | 30 Sep 2025 |
| VANGUARD GROUP INC | 4.7% | $2,670,221 | 408,222 | The Vanguard Group | 30 Sep 2025 | |||
| INTEGRATED CORE STRATEGIES (US) LLC | 0.2% | -92% | $52,341 | -$1,530,881 | 42,888 | -97% | Integrated Core Strategies (US) LLC | 30 Sep 2026 |
As of 30 Jun 2026,
95
institutional investors reported holding
shares of
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI).
This represents
93%
of the company’s total
outstanding shares.
21.11M
Full value: 21,114,264 · shares · 30 Jun 202622.7M
Full value: 22,703,733 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
79%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 8.4% | 1,917,354 | 0% | 0.16% | $18,732,549 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.7% | 1,521,322 | -16% | 0.02% | $14,863,316 |
| ACORN CAPITAL ADVISORS, LLC | 6.7% | 1,518,113 | +427% | 4% | $14,831,964 |
| GOLDMAN SACHS GROUP INC | 6.3% | 1,424,658 | +50% | 0% | $13,918,908 |
| BlackRock, Inc. | 6.2% | 1,418,799 | +479% | 0% | $13,861,666 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 958,979 | +30% | 0% | $9,369,225 |
| Catalio Capital Management, LP | 4.1% | 940,855 | +4.8% | 1.7% | $9,192,153 |
| Avidity Partners Management LP | 4.1% | 924,487 | +99% | 1.4% | $9,032,238 |
| T. Rowe Price Investment Management, Inc. | 3.5% | 786,309 | -49% | 0.01% | $7,683,000 |
| TWO SIGMA INVESTMENTS, LP | 3.1% | 695,264 | +360% | 0.01% | $6,792,729 |
| Kalehua Capital Management LLC | 3% | 685,644 | 3.9% | $6,698,742 | |
| NEA Management Company, LLC | 2.5% | 576,780 | 0.35% | $5,635,141 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 531,231 | +158% | 0% | $5,191,417 |
| Ghisallo Capital Management LLC | 2.2% | 500,000 | 0.1% | $4,885,000 | |
| Soleus Capital Management, L.P. | 1.9% | 440,000 | 0% | 0.15% | $4,298,800 |
| UBS Group AG | 1.6% | 353,545 | +82% | 0% | $3,454,135 |
| STATE STREET CORP | 1.4% | 325,991 | +304% | 0% | $3,184,932 |
| Affinity Asset Advisors, LLC | 1.4% | 312,500 | -38% | 0.15% | $3,053,125 |
| Brevan Howard Capital Management LP | 1.4% | 309,817 | +46% | 0.04% | $3,026,912 |
| MILLENNIUM MANAGEMENT LLC | 1.3% | 305,676 | -27% | 0% | $2,986,455 |
| Boxer Capital Management, LLC | 1.3% | 302,536 | 0% | 0.22% | $2,955,777 |
| Davidson Kempner Capital Management LP | 1.3% | 300,000 | 0% | 0.05% | $2,931,000 |
| ACADIAN ASSET MANAGEMENT LLC | 1.3% | 298,997 | +20% | 0% | $2,916,000 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.3% | 297,460 | 0.32% | $2,906,184 | |
| Eversept Partners, LP | 1.2% | 276,174 | 0% | 0.15% | $2,698,220 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Headline period
Q2 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 603,427 | $738,065 | +$600,909 | $1.22 | 13 |
| 2026 Q2 | 21,114,264 | $206,350,504 | +$47,473,090 | $9.77 | 95 |
| 2026 Q1 | 17,581,515 | $97,927,900 | +$39,559,074 | $5.57 | 76 |
| 2025 Q4 | 9,456,135 | $69,598,197 | +$47,945,529 | $7.36 | 68 |
| 2025 Q3 | 2,947,949 | $19,279,960 | -$7,678,877 | $6.54 | 51 |
| 2025 Q2 | 4,384,748 | $18,898,424 | +$4,718,131 | $4.31 | 49 |
| 2025 Q1 | 3,312,099 | $12,386,156 | +$12,277,831 | $3.74 | 47 |